Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling.

Greevy RA Jr, Huizinga MM, Roumie CL, Grijalva CG, Murff H, Liu X, Griffin MR.

Clin Pharmacol Ther. 2011 Dec;90(6):813-9. doi: 10.1038/clpt.2011.228. Epub 2011 Nov 2.

PMID:
22048232
2.

Long term patterns of use after initiation of oral antidiabetic drug therapy.

Lamberts EJ, Nijpels G, Welschen LM, Hugtenburg JG, Dekker JM, Souverein PC, Bouvy ML.

Pharmacoepidemiol Drug Saf. 2011 Apr;20(4):351-8. doi: 10.1002/pds.2089. Epub 2010 Dec 23.

PMID:
21442684
3.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
4.
5.
6.

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.

PMID:
12453968
7.

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.

PMID:
17245800
8.

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.

PMID:
15927899
9.

Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study.

Huizinga MM, Roumie CL, Greevy RA, Liu X, Murff HJ, Hung AM, Grijalva CG, Griffin MR.

Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1108-12. doi: 10.1002/pds.2035.

PMID:
20878643
10.
11.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
12.

Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation).

Kogut SJ, Andrade SE, Willey C, Larrat EP.

Pharmacoepidemiol Drug Saf. 2004 Sep;13(9):591-8.

PMID:
15362081
13.

Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.

Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM.

Diabetes Care. 2007 Jul;30(7):1689-93. Epub 2007 Apr 17.

PMID:
17440170
14.

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.

Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024 .

PMID:
19232035
15.

Sustained hyperglycemia among patients with diabetes: what matters when action is needed?

Lafata JE, Dobie EA, Divine GW, Ulcickas Yood ME, McCarthy BD.

Diabetes Care. 2009 Aug;32(8):1447-52. doi: 10.2337/dc08-2028.

16.

Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.

Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.

Curr Med Res Opin. 2010 Jul;26(7):1697-703. doi: 10.1185/03007995.2010.489029.

PMID:
20465367
17.

Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.

Cheong C, Barner JC, Lawson KA, Johnsrud MT.

Clin Ther. 2008 Oct;30(10):1893-907. doi: 10.1016/j.clinthera.2008.10.003.

PMID:
19014846
18.

Persistence patterns with oral antidiabetes drug treatment in newly treated patients--a population-based study.

Grégoire JP, Sirois C, Blanc G, Poirier P, Moisan J.

Value Health. 2010 Sep-Oct;13(6):820-8. doi: 10.1111/j.1524-4733.2010.00761.x.

19.
20.

Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.

Aquilante CL, Zhang W, McCollum M.

Curr Med Res Opin. 2007 Mar;23(3):489-94.

PMID:
17355730

Supplemental Content

Support Center